Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022
About Hepatic Encephalopathy (HE) Therapeutics
HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
Technavio’s analysts forecast the global hepatic encephalopathy (HE) therapeutics market to grow at a CAGR of 5.35% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global hepatic encephalopathy (HE) therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022
Technavio recognizes the following companies as the key players in the global hepatic encephalopathy (HE) therapeutics market: ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt, and Valeant.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is technological advances. The adoption of advanced technology to improve the safety profile of the therapeutics used to treat HE is increasing. For instance, the Multi Matrix (MMX) technology, which is offered by COSMO PHARMACEUTICALS, is one such promising development. The MMX technology helps deliver antibiotics directly into the colon.”
According to the report, one driver in the market is availability of patient-focused programs to assist disease management. Vendors in the market conduct several programs to help patients manage HE. For instance, Salix conducts the Hepatic Encephalopathy Living Program (H.E.L.P.), which provides support to patients and their caregivers to manage HE. H.E.L.P. provides a 24/7 helpline service that is managed by trained nurses to address queries and make reminder calls about medicine refills and doctor visits.
Further, the report states that one challenge in the market is late and inaccurate diagnosis. The symptoms of HE are non-specific. They include personality changes slurred speech, poor coordination, lethargy, confusion, trembling hands, and bad breath. The symptoms are usually subtle and may be attributed incorrectly to other causes. This can cause delays in diagnosis or inaccurate diagnosis. The absence of an agreed standard procedure or diagnostic test is also a challenge that compounds concerns about the diagnosis of the disease.
ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt, and Valeant.